BRAF (gene)

BRAF Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 1UWH , 1UWJ... Aliases BRAF , B-RAF1, BRAF1, NS7, RAFB1, B-Raf, B-Raf proto-oncogene, serine/threonine kinase...

Variations of BRAF mutant allele percentage in melanomas. | Sigma-Aldrich

Variations of BRAF mutant allele percentage in melanomas. by Zofia Hélias-Rodzewicz, Elisa Funck-Brentano, Laure Baudoux, Chan Kwon Jung, Ute Zimmermann, Cristi Marin, Thierry Clerici, Catherine Le...

갑상선결절과 BRAF 유전자에 관하여

출처: Molecular targeted therapy of BRAF-mutant colorectal cancer Michel Ducreux, Ali Chamseddine ,and Maximiliano Gelli 2. BRAF 유전자의 임상적 활용 출처: Molecular targeted therapy of BRAF-mutant colorectal cancer Michel Ducreux, Ali Chamseddine...

[SDG3]BRAF 耐性 생긴 흑색 피부암 원인 찾았다...KIST 세계최초

폴리아민 생합성 억제를 통한 BRAF 억제 항암제 내성 극복=(위) 흑색종은 BRAF 억제 항암제 투여에도 항암제 내성이 발생하여 암이 재발함. (아래) 폴리아민 생합성 억제와 BRAF 억제 항암제를 조합하면 암의 재발을 막고 완치 가능성이 증가할 수 있음.(출처=KIST)

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Nature

Preclinical experiments demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts 4 . Toxicology studies...

'BRAF'

박병선 · (한국과학기술연구원) · 김택훈 · (한국과학기술연구원) · Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance ... ; 양수렴 · (Memorial Sloan Kettering Cancer Center) · Tumor-agnostic genomic and clinical analysis of · fusions identify actionable targets · Clin. Cancer Res. ; 박상현 · (전남대학교 의과대학, KAIST) · 유원지 · 김상겸 · 김민환 · 김준 · (KAIST) · Overcoming ...

BRAF-mutant ctDNA predicts outcomes | Nature Reviews Clinical Oncology

Now, an analysis of samples from two clinical trials provides further evidence that BRAF mutations present in ctDNA can be used to predict clinical outcome.

난치성 BRAF 변이 폐암, 항암제 내성 원인 규명 - 보건산업 대표 종합전문지-보건신문

reactivation of MAPK signaling induces acquired resistance to GSK2118436 in BRAF V600E mutant NSCLC cell lines'(BRAF V600E 변이 비소세포폐암 세포에서의 타핀라에 의한 획득 내성 기전)의 제목으로 게재, 발표됐다.

Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in KRAS- and BRAF....

Editor’s summary · Inhibitors of the Ras-MAPK pathway are used to treat cancers carrying RAS and BRAF mutations. Zhang et al. performed a CRISPR-based screen to find modulators of the MAPK pathway and found that protein phosphatase 6 (PP6) increased sensitivity to MAPK pathway inhibitors. Deletion of the catalytic subunit of PP6 promoted the growth of KRAS- and BRAF-mutant cells in spheroid cultures and in mice in an NF-κB–dependent manner and increased their resistance to MAPK pathway i...

Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH | Science

Getting all stressed out by vitamin C · Few experimental cancer therapies have incited as much debate as vitamin C. Yet the mechanistic effect of vitamin C on cancer cells is still poorly understood. Yun et al. studied human colorectal cancer cells with KRAS or BRAF mutations and found that they “handle” vitamin C in a different way than other cells, ultimately to their detriment (see the Perspective by Reczek and Chandel). Because a certain receptor is up-regulated in the mutant cells, th...